Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9542594 | 0.88 | ALDH1A1 (0.53) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL24871065 | 0.85 | HPGD (0.57) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL1866841 | 0.85 | CASP1 (0.56) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL114035 | 0.85 | CASP1 (0.56) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL5093434 | 0.84 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL13956306 | 0.84 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL8091887 | 0.83 | KDM4E (0.49) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL13956284 | 0.81 | HPGD (0.51) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL8421528 | 0.79 | SMN1; SMN2 (0.61) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL9407588 | 0.78 | CASP1 (0.59) | KDM4EALDH1A1HPGDHSD17B10NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160851-A1 | Substituted piperidine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| EP-1636207-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111032-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160851-A1 | Substituted piperidine carbamates | LIPE, PNLIP, LIPC | KDM4E 607/4885ALDH1A1 1044/4885HPGD 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.